Table 3 |
|||
|
Change in Outcome Measures after 8 weeks (Intention-to-treat analysis) (n = 55-60) |
|||
|
Variable |
Blend 1 (mean ± SD) |
Blend 2 (mean ± SD) |
Placebo (mean ± SD) |
|
|
|||
|
Endothelial Function |
|||
|
Flow-mediated dilatation, % |
0.70 ± 3.70 |
0.70 ± 3.80 |
0.60 ± 3.70 |
|
Stimulus-adjusted response measure |
-0.02 ± 0.23 |
-0.02 ± 0.21 |
-0.03 ± 0.21 |
|
Flow-mediated dilatation, % (acute effects) |
1.1 ± 3.70 |
0.7 ± 3.5 |
-0.3 ± 5.4 |
|
Serum Measures |
|||
|
Insulin, pmol/L |
68.06 ± 311.83 |
18.06 ± 213.21 |
15.97 ± 202.79 |
|
Fasting plasma glucose, mmol/L |
0.03 ± 1.44 |
0.16 ± 1.47 |
0.38 ± 1.58 |
|
Anthropometric Measures |
|||
|
Body Weight, kg |
0.40 ± 2.20 |
0.30 ± 2.80 |
0.40 ± 2.20 |
|
Body Mass Index, kg/m2 |
0.10 ± 0.80 |
0.10 ± 1.00 |
0.10 ± 0.80 |
|
Lipid Panel |
|||
|
Total Cholesterol, mmol/L |
0.08 ± 0.47 |
0.08 ± 0.60 |
0.03 ± 0.52 |
|
High Density Lipoprotein (HDL), mmol/L |
0.04 ± 0.17 |
0.04 ± 0.12 |
0.06 ± 0.15 |
|
Total Cholesterol/HDL |
-0.10 ± 0.60 |
-0.10 ± 0.80 |
-0.30 ± 0.70 |
|
Triglycerides, mmol/L |
0.02 ± 0.64 |
-0.01 ± 0.71 |
-0.13 ± 0.68 |
|
Low Density Lipoprotein (LDL), mmol/L |
-0.02 ± 0.53 |
0.08 ± 0.62 |
0.02 ± 0.53 |
|
|
|||
|
p > 0.05 for all pairwise comparisons |
|||
|
Ali et al. Nutrition Journal 2011 10:72 doi:10.1186/1475-2891-10-72 |
|||
